Harpreet Singh. Allogeneic Cell Therapies Summit

The chief sci­en­tist at Ger­man/US biotech hy­brid Im­mat­ics is mov­ing to the helm. Here's his to-do list

Just a few months af­ter launch­ing their 4th clin­i­cal tri­al for a unique brand of cell ther­a­pies, the Ger­man-US hy­brid biotech Im­mat­ics is pro­mot­ing the biotech’s long-time chief sci­en­tist and co-founder to the helm.

Harpreet Singh, CSO and head of the Hous­ton branch of the com­pa­ny — which is al­lied with in­ves­ti­ga­tors at MD An­der­son — has been pro­mot­ed to over­all CEO, a post which gives him over­sight of a grow­ing slate of tri­als for adop­tive T cell ther­a­pies, bis­pecifics with a group of part­ners that in­cludes Am­gen, Roche and Gen­mab as well as an off-the-shelf ap­proach to these new can­cer ther­a­pies. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.